Aerie pharmaceuticals completes enrollment of its first phase 3 clinical trial of netarsudil ophthalmic solution in japan

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first phase 3 clinical trial of netarsudil ophthalmic solution in japan, comparing netarsudil ophthalmic solution 0.02% (“netarsudil”),
AERI Ratings Summary
AERI Quant Ranking